Whether there is a molecular subtype of HNSCC, and more specifically OSCC, driven by MET mutation and/or amplification that confers a susceptibility to targeted agents, needs to be further examined in sufficiently large and well-described patient cohorts [7]. The gene discussed is MET; the disease is head and neck squamous cell carcinoma.